Bissinger Oliver, Kolk Andreas, Drecoll Enken, Straub Melanie, Lutz Christina, Wolff Klaus-Dietrich, Götz Carolin
Department of Oral and Maxillofacial Surgery, Klinikum Rechts der Isar, Technische Universität München, D-81675 Munich, Germany.
Institute of Pathology, Klinikum Rechts der Isar, Technische Universität München, D-81675 Munich, Germany.
Exp Ther Med. 2017 Nov;14(5):4620-4626. doi: 10.3892/etm.2017.5120. Epub 2017 Sep 18.
Survival periods of patients following surgical therapy of oral squamous cell carcinoma (OSCC) have previously been demonstrated to decrease over recent decades. Epidermal growth factor receptor (EGFR) and Cortactin are molecular markers that are important in tumour progression and development, and interact within the EGF pathway. Although EGFR antibody therapy exists, sufficient efforts for increased survival are still lacking due to the present limited response rates. The aim of the present study was to examine the association between EGFR and Cortactin expression on survival rates of OSCC patients and to determine whether EGFR and Cortactin expression levels are associated with advanced tumor sizes and lymphnode-metastases. In total, 222 OSCC patients were included in the study. EGFR and Cortactin expression in tumor tissue was evaluated by immunohistochemistry. Cox regression was used for survival analysis. Categories were tested for associations by using cross tabs (Chi-square test). Groups were compared by the non-parametric Mann Whitney U-test. Probabilities of less than 0.05 were considered significant and significant expression of Cortactin was observed in Advanced Union Internationale Contre le Cancer stage (P=0.032), including advanced tumour stage (P=0.021) and lymph node metastasis (P=0.049). High Cortactin expression was significantly associated with poorer survival rates (P=0.037). Further Cortactin expression was not associated with extracapsular spread, however EGFR exhibited a significant association (P=0.034). Neither EGFR nor Cortactin expression was correlated to grading. EGFR and Cortactin co-expression was demonstrated to be significantly associated with poorer survival rates in OSCC patients, suggesting that identification of predictive biomarkers for adjuvant therapies are of primary concern in OSCC. In particular, efficient dual-target therapy may act as an appropriate therapy to improve survival time for patients at advanced OSCC tumor stages.
先前已证明，近几十年来口腔鳞状细胞癌（OSCC）患者术后的生存期有所缩短。表皮生长因子受体（EGFR）和皮质肌动蛋白是在肿瘤进展和发展中起重要作用的分子标志物，且在表皮生长因子（EGF）途径中相互作用。尽管存在EGFR抗体疗法，但由于目前的有效率有限，在提高生存率方面仍缺乏足够的努力。本研究的目的是探讨EGFR和皮质肌动蛋白表达与OSCC患者生存率之间的关联，并确定EGFR和皮质肌动蛋白表达水平是否与肿瘤大小进展和淋巴结转移相关。本研究共纳入222例OSCC患者。采用免疫组织化学法评估肿瘤组织中EGFR和皮质肌动蛋白的表达。采用Cox回归进行生存分析。通过交叉表（卡方检验）对类别间的关联性进行检验。采用非参数Mann Whitney U检验对组间进行比较。概率小于0.05被认为具有统计学意义，且在国际抗癌联盟（UICC）晚期阶段观察到皮质肌动蛋白的显著表达（P=0.032），包括肿瘤晚期（P=0.021）和淋巴结转移（P=0.049）。高皮质肌动蛋白表达与较差的生存率显著相关（P=0.037）。此外，皮质肌动蛋白表达与包膜外扩散无关，但EGFR与之存在显著关联（P=0.034）。EGFR和皮质肌动蛋白的表达均与分级无关。EGFR和皮质肌动蛋白的共表达被证明与OSCC患者较差的生存率显著相关，这表明确定辅助治疗的预测生物标志物是OSCC治疗的首要关注点。特别是，有效的双靶点治疗可能是改善晚期OSCC肿瘤患者生存时间的合适疗法。
